ASBP
Aspire Biopharma Holdings In
NASDAQ · Pharmaceuticals
$1.46
+0.14 (+10.61%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.20M | 2.09M | 2.38M |
| Net Income | 266.8K | 312.0K | 325.1K |
| EPS | — | — | — |
| Profit Margin | 12.1% | 14.9% | 13.7% |
| Rev Growth | +5.7% | +22.2% | +15.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 703.8K | 744.6K | 770.5K |
| Total Equity | 1.66M | 1.82M | 1.58M |
| D/E Ratio | 0.42 | 0.41 | 0.49 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 501.0K | 520.7K | 532.7K |
| Free Cash Flow | 197.3K | 259.9K | 336.6K |